Literature DB >> 32513799

Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis.

Antonia P Gunesch1,2,3, Francisco J Zapatero-Belinchón1,2,3, Lukas Pinkert4, Eike Steinmann5, Michael P Manns1,2, Gisbert Schneider6, Thomas Pietschmann2,3, Mark Brönstrup2,4, Thomas von Hahn7,2,3,8.   

Abstract

Several cationic amphiphilic drugs (CADs) have been found to inhibit cell entry of filoviruses and other enveloped viruses. Structurally unrelated CADs may have antiviral activity, yet the underlying common mechanism and structure-activity relationship are incompletely understood. We aimed to understand how widespread antiviral activity is among CADs and which structural and physico-chemical properties are linked to entry inhibition. We measured inhibition of Marburg virus pseudoparticle (MARVpp) cell entry by 45 heterogeneous and mostly FDA-approved CADs and cytotoxicity in EA.hy926 cells. We analyzed correlation of antiviral activity with four chemical properties: pKa, hydrophobicity (octanol/water partitioning coefficient; ClogP), molecular weight, and distance between the basic group and hydrophobic ring structures. Additionally, we quantified drug-induced phospholipidosis (DIPL) of a CAD subset by flow cytometry. Structurally similar compounds (derivatives) and those with similar chemical properties but unrelated structures (analogues) to those of strong inhibitors were obtained by two in silico similarity search approaches and tested for antiviral activity. Overall, 11 out of 45 (24%) CADs inhibited MARVpp by 40% or more. The strongest antiviral compounds were dronedarone, triparanol, and quinacrine. Structure-activity relationship studies revealed highly significant correlations between antiviral activity, hydrophobicity (ClogP > 4), and DIPL. Moreover, pKa and intramolecular distance between hydrophobic and hydrophilic moieties correlated with antiviral activity but to a lesser extent. We also showed that in contrast to analogues, derivatives had antiviral activity similar to that of the seed compound dronedarone. Overall, one-quarter of CADs inhibit MARVpp entry in vitro, and antiviral activity of CADs mostly relies on their hydrophobicity yet is promoted by the individual structure.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Marburg virus; amiodarone; antiviral therapy; dronedarone; entry inhibitors; structure-activity relationships

Mesh:

Substances:

Year:  2020        PMID: 32513799      PMCID: PMC7526846          DOI: 10.1128/AAC.00143-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  53 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.

Authors:  Shanshan He; Billy Lin; Virginia Chu; Zongyi Hu; Xin Hu; Jingbo Xiao; Amy Q Wang; Cameron J Schweitzer; Qisheng Li; Michio Imamura; Nobuhiko Hiraga; Noel Southall; Marc Ferrer; Wei Zheng; Kazuaki Chayama; Juan J Marugan; T Jake Liang
Journal:  Sci Transl Med       Date:  2015-04-08       Impact factor: 17.956

3.  Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection.

Authors:  Pablo Gastaminza; Christina Whitten-Bauer; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-07       Impact factor: 11.205

4.  Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step.

Authors:  Rebecca M Mingo; James A Simmons; Charles J Shoemaker; Elizabeth A Nelson; Kathryn L Schornberg; Ryan S D'Souza; James E Casanova; Judith M White
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

5.  Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression.

Authors:  Margareta Reis; Anna Aberg-Wistedt; Hans Agren; Peter Höglund; Ann-Charlotte Akerblad; Finn Bengtsson
Journal:  Hum Psychopharmacol       Date:  2004-07       Impact factor: 1.672

6.  Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists.

Authors:  G R Nemerow; N R Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

7.  In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages.

Authors:  C M McCloud; T L Beard; S Kacew; M J Reasor
Journal:  Exp Mol Pathol       Date:  1995-02       Impact factor: 3.362

8.  Diverse CD81 proteins support hepatitis C virus infection.

Authors:  Mike Flint; Thomas von Hahn; Jie Zhang; Michelle Farquhar; Christopher T Jones; Peter Balfe; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

9.  Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for 'Orphan' Molecules.

Authors:  Michael Reutlinger; Christian P Koch; Daniel Reker; Nickolay Todoroff; Petra Schneider; Tiago Rodrigues; Gisbert Schneider
Journal:  Mol Inform       Date:  2013-02-07       Impact factor: 3.353

10.  PubChem 2019 update: improved access to chemical data.

Authors:  Sunghwan Kim; Jie Chen; Tiejun Cheng; Asta Gindulyte; Jia He; Siqian He; Qingliang Li; Benjamin A Shoemaker; Paul A Thiessen; Bo Yu; Leonid Zaslavsky; Jian Zhang; Evan E Bolton
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  9 in total

1.  Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening.

Authors:  Jennifer M Pfaff-Kilgore; Edgar Davidson; Kathryn Kadash-Edmondson; Mayda Hernandez; Erin Rosenberg; Ross Chambers; Matteo Castelli; Nicola Clementi; Nicasio Mancini; Justin R Bailey; James E Crowe; Mansun Law; Benjamin J Doranz
Journal:  Cell Rep       Date:  2022-05-24       Impact factor: 9.995

Review 2.  Nuisance compounds in cellular assays.

Authors:  Jayme L Dahlin; Douglas S Auld; Ina Rothenaigner; Steve Haney; Jonathan Z Sexton; J Willem M Nissink; Jarrod Walsh; Jonathan A Lee; John M Strelow; Francis S Willard; Lori Ferrins; Jonathan B Baell; Michael A Walters; Bruce K Hua; Kamyar Hadian; Bridget K Wagner
Journal:  Cell Chem Biol       Date:  2021-02-15       Impact factor: 8.116

3.  Spiers Memorial Lecture: Analysis and de novo design of membrane-interactive peptides.

Authors:  Huong T Kratochvil; Robert W Newberry; Bruk Mensa; Marco Mravic; William F DeGrado
Journal:  Faraday Discuss       Date:  2021-12-24       Impact factor: 4.394

4.  Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2.

Authors:  Tia A Tummino; Veronica V Rezelj; Benoit Fischer; Audrey Fischer; Matthew J O'Meara; Blandine Monel; Thomas Vallet; Ziyang Zhang; Assaf Alon; Henry R O'Donnell; Jiankun Lyu; Heiko Schadt; Kris M White; Nevan J Krogan; Laszlo Urban; Kevan M Shokat; Andrew C Kruse; Adolfo García-Sastre; Olivier Schwartz; Francesca Moretti; Marco Vignuzzi; Francois Pognan; Brian K Shoichet
Journal:  bioRxiv       Date:  2021-03-24

5.  Evaluation of Phenol-Substituted Diphyllin Derivatives as Selective Antagonists for Ebola Virus Entry.

Authors:  Caroline B Plescia; Aaron R Lindstrom; Maritza V Quintero; Patrick Keiser; Manu Anantpadma; Robert Davey; Robert V Stahelin; V Jo Davisson
Journal:  ACS Infect Dis       Date:  2022-03-31       Impact factor: 5.578

6.  Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization.

Authors:  J J Patten; Patrick T Keiser; Deisy Morselli-Gysi; Giulia Menichetti; Hiroyuki Mori; Callie J Donahue; Xiao Gan; Italo do Valle; Kathleen Geoghegan-Barek; Manu Anantpadma; RuthMabel Boytz; Jacob L Berrigan; Sarah H Stubbs; Tess Ayazika; Colin O'Leary; Sallieu Jalloh; Florence Wagner; Seyoum Ayehunie; Stephen J Elledge; Deborah Anderson; Joseph Loscalzo; Marinka Zitnik; Suryaram Gummuluru; Mark N Namchuk; Albert-László Barabási; Robert A Davey
Journal:  iScience       Date:  2022-08-13

7.  Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity.

Authors:  Francisco J Zapatero-Belinchón; Rina Ötjengerdes; Julie Sheldon; Benjamin Schulte; Belén Carriquí-Madroñal; Graham Brogden; Laura M Arroyo-Fernández; Florian W R Vondran; Benjamin Maasoumy; Thomas von Hahn; Gisa Gerold
Journal:  Cells       Date:  2021-06-29       Impact factor: 6.600

8.  Implicitly perturbed Hamiltonian as a class of versatile and general-purpose molecular representations for machine learning.

Authors:  Amin Alibakhshi; Bernd Hartke
Journal:  Nat Commun       Date:  2022-03-10       Impact factor: 17.694

9.  Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.

Authors:  Tia A Tummino; Veronica V Rezelj; Benoit Fischer; Audrey Fischer; Matthew J O'Meara; Blandine Monel; Thomas Vallet; Kris M White; Ziyang Zhang; Assaf Alon; Heiko Schadt; Henry R O'Donnell; Jiankun Lyu; Romel Rosales; Briana L McGovern; Raveen Rathnasinghe; Sonia Jangra; Michael Schotsaert; Jean-René Galarneau; Nevan J Krogan; Laszlo Urban; Kevan M Shokat; Andrew C Kruse; Adolfo García-Sastre; Olivier Schwartz; Francesca Moretti; Marco Vignuzzi; Francois Pognan; Brian K Shoichet
Journal:  Science       Date:  2021-06-22       Impact factor: 47.728

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.